Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 8:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,276 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Completed Phase 2 Interventional

Treatment for Patients With Metastatic Thyroid Cancer

NCT00176748
View directory record Official record
Conditions
Thyroid Cancer
Interventions
AG 6013736
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

NCT01637285
View directory record Official record
Conditions
Healthy
Interventions
PF-04856883
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 31, 2015 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 3 Interventional Results available

Surgical Pain After Inguinal Hernia Repair (SPAIHR)

NCT00551135
View directory record Official record
Conditions
Pain, Postoperative, Hernia, Inguinal
Interventions
Pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
17 Years to 75 Years · Male only
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
Birmingham, Alabama • Glendale, California • Laguna Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 27, 2026, 8:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Instrumented Data Exchange for Ataxia Study

NCT04268147
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Friedreich Ataxia
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
12 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

NCT01989143
View directory record Official record
Conditions
Healthy
Interventions
PF-06480605, Placebo
Drug
Lead sponsor
Telavant, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 27, 2026, 8:12 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

NCT02306876
View directory record Official record
Conditions
Healthy
Interventions
PF-06412562 3mg BID, PF-06412562 15mg BID, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Arcadia, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma

NCT00065468
View directory record Official record
Conditions
Carcinoma, Renal Cell, Kidney Neoplasms
Interventions
Interferon Alfa, CCI-779, Interferon Alfa and CCI-779
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
48
States / cities
Little Rock, Arkansas • La Verne, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 27, 2026, 8:12 AM EDT
Recruiting Phase 1 Interventional

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

NCT06131840
View directory record Official record
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
Interventions
PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV)
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 1 Interventional Results available

PF-06669571 In Subjects With Idiopathic Parkinson's Disease

NCT02565628
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
PF-06669571, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
New Haven, Connecticut • Hallandale, Florida • Hollywood, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 4 Interventional

Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia

NCT01226667
View directory record Official record
Conditions
Fibromyalgia
Interventions
Pregabalin
Drug
Lead sponsor
Osteoporosis Medical Center, Beverly Hills, CA
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Beverly Hills, California • Huntington Beach, California • Tucson, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 27, 2026, 8:12 AM EDT
Active, not recruiting Phase 3 Interventional

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
216
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

NCT00769067
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Erlotinib, PF-00299804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
26
States / cities
Muscle Shoals, Alabama • Montebello, California • Bridgeport, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

NCT00427895
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
26
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 1 Interventional

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

NCT01005472
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
sunitinib malate, temozolomide
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 3 Interventional

An Open-Label Trial of Pregabalin in Patients With Fibromyalgia

NCT00151528
View directory record Official record
Conditions
Fibromyalgia
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
93
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 2 Interventional

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide

NCT01543919
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
PH-797804, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
45
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 27, 2026, 8:12 AM EDT
Terminated Phase 1 Interventional Results available

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

NCT05061537
View directory record Official record
Conditions
Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma
Interventions
PF-07263689, Sasanlimab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

NCT01284062
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Anrukinzumab, placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 2 Interventional

A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)

NCT00275197
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Sertraline and Elzasonan Combination, Sertraline, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Beverly Hills, California • Norwich, Connecticut • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2008 · Synced Oct 27, 2026, 8:12 AM EDT
Terminated Phase 2 Interventional Results available

Safety And Efficacy Of Tanezumab In Patients With Chronic Pancreatitis

NCT01146561
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Tanezumab, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Naples, Florida • Wellington, Florida • Tupelo, Mississippi + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 3 Interventional

A Study Of Diflucan In Children With Ringworm Of The Scalp

NCT00645242
View directory record Official record
Conditions
Tinea Capitis
Interventions
fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 12 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
28
States / cities
Montgomery, Alabama • Little Rock, Arkansas • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT00969813
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 27, 2026, 8:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

NCT05478603
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
PF-07081532
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 27, 2026, 8:12 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

NCT06597396
View directory record Official record
Conditions
Post-COVID Condition, Fatigue Symptom
Interventions
Abrocitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 27, 2026, 8:12 AM EDT